Ann Eldred

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Lars Erik Kristensen, Mauro Waldemar Keiserman, Kim Papp et al. · Annals of the Rheumatic Diseases · 2021 · 143 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Andrew J.K. Östör, Filip Van den Bosch, Kim Papp et al. · Annals of the Rheumatic Diseases · 2021 · 106 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

Philip J. Mease, H. Kellner, Akimichi Morita et al. · Annals of the Rheumatic Diseases · 2018 · 53 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

ABT‐719 for the Prevention of Acute Kidney Injury in Patients Undergoing High‐Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial

Peter A. McCullough, Elliott Bennett‐Guerrero, Lakhmir S. Chawla et al. · Journal of the American Heart Association · 2016 · 40 citations · Full text

Medicine, Perioperative Medicine, Pharmacotherapy +14

Activated ERK2 Interacts with and Phosphorylates the Docking Protein GAB1

Bijan Roshan, Crystal Kjelsberg, Katherine Spokes et al. · Journal of Biological Chemistry · 1999 · 37 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14